INDO US BIOTECH LTD
INDOUS · General/Diversified · NSE
₹105
Current Market Price
Fair Value (DCF)
₹133
Margin of Safety
+26.8%
Updated 1d ago
YieldIQ Score
87/100
Piotroski F-Score
8/9
Economic Moat
Wide
Confidence
30%
ROE
—
Debt/Equity
0.32
WACC
11.1%
Market Cap
₹211 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
22.0%
Return on capital employed
EV / EBITDA
12.8×
Enterprise multiple
Debt / EBITDA
0.8×
Leverage vs earnings
Interest Coverage
12.5×
EBIT covers interest
Current Ratio
5.31×
Short-term liquidity
Asset Turnover
1.06×
Revenue per ₹ of assets
Revenue CAGR (3Y)
27.5%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹105.18
Bear case
₹70.99
MoS -48.2%
Base case
₹133.32
MoS +21.1%
Bull case
₹152.46
MoS +31.0%
Ratio Trends
INDOUS · last 4 annual periods
ROE
20.7%
ROCE
20.4%
Operating Margin
—
Debt / Equity
0.19×
PE
—
EV / EBITDA
—
Historical Financials
INDOUS · Annual, last 4 years· amounts in ₹Cr unless noted
| Metric | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|
| Revenue | ₹50.1 Cr | ₹61.7 Cr | ₹72.8 Cr | ₹104 Cr | +27.5% |
| EBITDA | ₹6.9 Cr | ₹9.3 Cr | ₹11.0 Cr | ₹19.1 Cr | +40.3% |
| EBIT | — | — | — | — | — |
| PAT | ₹5.1 Cr | ₹7.2 Cr | ₹8.2 Cr | ₹16.3 Cr | +47.6% |
| EPS (diluted) | — | — | — | — | — |
| CFO | ₹2.7 Cr | ₹0.5 Cr | ₹2.2 Cr | ₹1.4 Cr | -19.3% |
| CapEx | ₹-4.0 Cr | ₹-1.8 Cr | ₹-2.6 Cr | ₹-0.9 Cr | — |
| FCF | ₹-1.3 Cr | ₹-1.3 Cr | ₹-0.4 Cr | ₹0.6 Cr | — |
| Total Assets | ₹55.6 Cr | ₹69.5 Cr | ₹84.5 Cr | ₹97.8 Cr | +20.7% |
| Total Debt | ₹12.8 Cr | ₹11.6 Cr | ₹14.3 Cr | ₹14.8 Cr | +4.9% |
| Shareholders' Equity | ₹38.5 Cr | ₹54.5 Cr | ₹62.7 Cr | ₹78.5 Cr | +26.8% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
INDOUS vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
| SIKKO SIKKO INDUSTRIES LIMITED | -57.0% | 40 | Above Fair Value | 5.2% | — |
| NAGAFERT NAGARJUN FERT AND CHE LTD | +400.0% | 37 | Below Fair Value | — | — |
| NOVAAGRI NOVA AGRITECH LIMITED | +18.4% | 54 | Below Fair Value | 12.5% | — |
| NATHBIOGEN NATH BIO-GENES (I) LTD | +95.1% | 60 | Below Fair Value | 6.0% | — |
| NARMADA NARMADA AGROBASE LIMITED | -64.8% | 52 | Data Limited | 7.3% | — |
Click a ticker to view its fair-value analysis.
Dividend History
No dividend events recorded for INDOUS in the last 10 years.
AI Analysis Summary
Model-generated description of metrics. Not investment advice. INDO US BIOTECH LTD (INDOUS.NS) trades at 105.18 vs a model fair value of 133.32, a gap of 26.8%. Piotroski F-score: 8/9. Moat label: Wid...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of INDOUS →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for INDOUS →
Compare
Head-to-head with peers
Compare INDOUS side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse INDOUSNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.